How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

CLICK HERE FOR CME CREDIT

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology St. Michael’s Hospital